Agios Pharmaceuticals Inc (NASDAQ: AGIO) announced it will discontinue development of tebapivat for lower-risk myelodysplastic syndromes after the drug failed ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA